MedTrace Logo

Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

NCT05173896 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-12-09

No results posted yet for this study

Summary

In a randomized controlled trial the feasibility and effect of three months treatment with daily tadalafil, on cerebral blood flow/reactivity and cognition, is investigated in patients with cerebral small vessel disease.

Conditions

  • Cerebral Small Vessel Diseases
  • Stroke, Ischemic

Interventions

DRUG

Tadalafil 20 MG

Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.

DRUG

Placebo

Daily dose of oral over-encapsulated placebo tablets for three months.

Sponsors & Collaborators

  • Danish Research Centre for Magnetic Resonance

    collaborator OTHER

  • Bispebjerg Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • The Novo Nordic Foundation

    collaborator OTHER

  • Nordsjaellands Hospital

    collaborator OTHER

  • Christina Kruuse

    lead OTHER

Principal Investigators

  • Christina Kruuse, MD, Prof · Herlev Gentofte Hospital, Department of Neurology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2024-09-23
Completion
2029-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05173896 on ClinicalTrials.gov